Skip to main content
Sign In

Search

Search for a Specific Type of Clinical Trial
Note: This page will take a moment to download because of the quantity of trials.

Feedback

Did you have problems using this page? Please fill out our Feedback Form

Clinical Trials

Volunteer to Be Part of a Research Study

Page through all School of Medicine clinical and research trials below. There are two categories:

  • Detailed Trial Descriptions, submitted by researchers, includes trial specifics and contact information.

  • Additional Clinical Trials, which include basic study details. To contact the researcher either Google the PI (primary investigator) name or use our campus directory.

If you are a researcher seeking volunteers and your study is not posted, please
submit your Web ad here.
  

Detailed Trial Descriptions

 Results From Research and Clinical Trials : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 5, items 1 to 30 of 130.
TitleStudy GoalsEligibility CriteriaContact Information
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 5, items 1 to 30 of 130.
Are you taking medications for diabetes and resulting kidney complications? 13-1419
To evaluate a new investigational drug for people with Type 2 diabetes and kidney disease.
Person 18+ who are not of child bearing potential (f female) with type 2 diabetes and currently taking medication for kidney disease. You must be able to attend at least 6 office visits over 16 weeks.
PI: Rasouli, Neda
  • 720-848-7174
  • T2DMresearch@ucdenver.edu
MS Volunteers Needed for Research Study 12-1388
Looking to see if there is a cognitive improvement with the treatment of oral estriol as compared to oral placebo.
We are looking for: • Women 18-50 years old • Diagnosed with definite relapsing-remitting, secondary-progressive multiple sclerosis or primary-progressive multiple sclerosis • MS disease duration of 15 years or less • On stable dose of standard MS treatment with Copaxone®, Betaseron® (or Extavia®), Rebif®,Avonex®, Gilenya®, Aubagio®, Tecfidera®, or no treatment ----You are not eligible for the study if you are pregnant, breast-feeding, smoke, or have other serious medical conditions.
PI: Corboy, John
  • Brittany Kling
  • Brittany.Kling@ucdenver.edu
Apoyo con Cariño: Improving Palliative Care for Latinos with Cancer 12-0592
We want to understand if a patient navigator can help Latino patients and their family caregivers deal with cancer. Our project hopes to improve palliative or comfort care to patients with advanced cancer. The goal is to prevent or relieve suffering for people facing serious illness. Research is needed to find out if a patient navigator can help patients and family caregivers.
Adults (18 years and older) who self-identify as Latino and have Stage III-IV cancer.
PI: Fischer MD, Stacy
  • 303-724-7410
  • danielle.kline@ucdenver.edu
Seeking Adults with NO History of Eczema, Allergies or Asthma HS-2581
The purpose of this study is to determine why some individuals with atopic dermatitis are at increased risk for skin infections.
Males and females between 18 and 64years of age with no history of Allergies, Eczema, or Asthma
PI: Leung, Donald
  • 303-270-2222
  • lairsmithj@njhealth.org
SPIROMICS-Subpopulations and Intermediate Outcome Measures in COPD Study HS-2678
To identify subpopulations of COPD patients in order to develop newer and more effective treatments and to clearly define measureable end points so that treatment effects may be accurately assessed in a shorter period of time.
Be willing to undergo study procedures Be between the age of 40 and 80 years old Have smoked fewer than one pack of cigarettes per day for one year OR have smoked more than one pack of cigarettes per day for 20 years
PI: Bowler, Russell
  • 303-270-2827
  • HerrudT@njHealth.org
Psychiatric Medication Study 11-0965
We are looking for volunteers to participate in a research study investigating how psychiatric medications are processed in people who are diagnosed with HIV-1 compared to subjects who are on psychiatric medications who are HIV-negative. You can participate in this study if you are HIV negative and taking certain psychiatric medications.
To Qualify: Must between the ages of  2 to <25 years; Be HIV-Negative; On a steady dose of Psychiatric Medication (Celexa, Lexapro, Risperdal, Zoloft, Prozac, Paxil or generic equivalents)
PI: McFarland, Elizabeth
  • 720-777-6257
  • jenna.wallace@childrenscolorado.org
HEALTHY MEN AND WOMEN 60-85 YEARS OLD Wanted to participate in a research study 13-2594
To test whether interrupting prolonged sitting with short bouts of moderate intensity walking can improve health
We are looking for men and women who:  Are age 60-85 years old  Healthy – no diagnosed disease  Not on glucose lowering medication  Do not participate in regular exercise  Ambulatory – able to walk without assistance  Are non-smokers
PI: Lyden, Kate
  • Kate Lyden
  • kate.lyden@ucdenver.edu
Healthy Female Adolescents Needed!!! 07-0816
For brain imaging research study on how the brain works with we taste sweets or receive money. Your participation could help us to develop treatments and preventive measures for anorexia nervosa and obesity
Healthy females 11 to 21 who are right-handed, free of medication with no serious medical conditions, permanent metal implants or braces/retainers, and are at a healthy body weight.
PI: Frank, Guido
  • 720-777-4026
  • imaging.research@childrenscolorado.org
Healthy Females needed! Ages 11 to 29 07-0816
For brain imaging research study on how the brain works with we taste sweets or receive money.  Your participation could help us to develop treatments and preventive measures for anorexia nervosa and obesity
Healthy females 11 to 29 who are right-handed, free of medication with no serious medical condition or permanent metal implants or braces/retainers.
PI: Frank, Guido
  • 720-777-4026
  • imaging.research@childrenscolorado.org
We are looking for Healthy Women to participate in a research study on.....Females, Aging, Metabolism, and Exercise (FAME) 12-1157
To examine the role that female sex hormones play in metabolism, energy expenditure, physical activity and chronic disease.
Healthy women 40-60 who have regular menstrual cycles and using no hormonal contraceptives
PI: Kohrt, Wendy
  • 720-848-6399
  • Kimberly.Harner@ucdenver.edu
Diabetes? 12-0923
To evaluate study medication for Type 2 Diabetes.
Person 18+ diagnosed with Type 2 Diabetes
PI: Rasouli, Neda
  • 720-848-7174
  • T2DMresearch@ucdenver.edu
Do you have Diabetes? 13-0131
To find the best combination drug treatment for type 2 diabetes
Persons who have had diabetes for less than 5 years and metformin is the only diabetes medication you are taking.
PI: Rasouli, Neda
  • 720-848-7174
  • Bradley.wine@ucdenver.edu
Type 1 Diabetes Research Study 11-0693
To study the effects of an FDA-approved medication on metabolism and blood vessel function.
Person 25-50 with type 1 diabetes who exercise vigorously less than four times per week and have normal blood pressure
PI: Schauer, Irene
  • 720-848-6690
  • Ellen.Lyon@ucdenver.edu
CHILDHOOD and ADOLESCENT MIGRAINE PREVENTION STUDY 12-0776
to test two medicines for migraine prevention in children and teens. We want to see if amitriptyline and/or topiramate are better than placebo (sugar pill) in reducing headache frequency.
Children 8-17 who have migraine headaches
PI: Kedia, Sita
  • 720-777-8588
  • headacheresearch@childrenscolorado.org
Volunteers are invited for a research studying looking at pain in knee osteoarthritis 12-1188
To better understand the complex experience of pain for people with knee osteoarthritis
Persons 50 or older who have been diagnosed with knee osteoarthritis
PI: Stevens-Lapsley, Jennifer
  • 303-724-9590
  • kneepain@ucdenver.edu
Just received VARIVAX, the chickenpox vaccine? 13-2122
Research study looking at the immune response to chickenpox vaccine
Age 12 months to 50 years; able to enroll in study within 10 days of vaccination.
PI: Levin, Myron
  • 303/724-2454
  • nancy.lang@ucdenver.edu
Healthy Women Needed for Cardiovascular Research Study 06-0537
The purpose of this study is to investigate how the menopause transition and the loss of estrogen impacts the health and function of arteries in women.
- Premenopausal women 18-49 years, Perimenopausal women 40-55 years and Postmenopausal women 45-70 years - Non-smokers - Volunteers should NOT be taking Birth Control or Hormone Replacement Therapy (HRT) or exercising vigorously more than 2 days per week.
PI: Moreau, Kerrie
  • 720-848-6419
  • shape.study@ucdenver.edu
Do You Use a Wood Burning Stove? 13-1740
This study will be evaluating the effects that a wood burning stove has on the quality of the indoor air in your home and your respiratory health.
People who use wood burning stoves for cooking or to heat their homes in the winter.
PI: Meeks, Paula
  • 303-724-2878 or 855-347-6850 (Toll Free)
  • marylou.robinson@ucdenver.edu
We are seeking physically active men for a research study: PTH and Calcium Response to Exercise (PACE) 12-0767
Determine whether preventing the decrease in blood calcium levels prevents an increase in parathyroid hormone, or PTH, which causes bone to release calcium.
 Men in generally good health, aged 18-45 years  Regularly cycle for exercise and can ride for an hour at a vigorous intensity  Not taking medication for osteoporosis  No history of asthma
PI: Wendy, Kohrt
  • 303-724-6529
  • vanessa.sherk@ucdenver.edu
Research investigating the influence of a Monopoly Game on Subtle Behaviors 14-0719
This research study plans to learn more about how a stressful game of monopoly will influence subtle behaviors.
To qualify for the study you must be: Between the ages 19-25 Consider yourself Hispanic/Latino Born in the United States Be a non-smoker Have played the game Monopoly before
PI: Cardel, PhD, RD, Michelle
  • 303-724-9050
  • Michelle.Cardel@UCDenver.edu
Looking for HIV-positive individuals to participate in a research study on Lipodystrophy Syndrome 14-1595
We are conducting a study of the relationship of bacteria in the gut to HIV infection. We are interested in finding out whether people who have metabolic diseases such as lipodystrophy (loss of fat tissue) as complications of long term antiretroviral therapy have a different makeup of their gut bacteria. We are therefore seeking volunteers with HIV infection to participate in a study of bacteria in the stool.
-Non-obese HIV positive individuals who are 18-65 years old -Either not currently on antiretroviral therapy (ART naïve or off therapy for 6 months or greater) or on effective ART with documented suppression for 6 months or greater. -We are particularly interested in enrolling subjects with lipodystrophy, but would also like to enroll individuals without lipodystrophy as controls.
PI: Lozupone, PhD, Catherine
  • 303-724-0762
  • christine.griesmer@ucdenver.edu
Looking for HIV-positive and HIV-negative individuals to participate in a research study on smoking and lung disease 13-2986
We are conducting a study to look at lung complications and disease in HIV/AIDS.
-Between 30 and 70 years old -Both HIV-positive and HIV-negative individuals with and without chronic obstructive pulmonary disease (COPD) -If HIV-positive, on a stable three-drug ART regimen with undetectable viral load for past 6 months
PI: Campbell, MD, Thomas
  • 303-724-0762
  • christine.griesmer@ucdenver.edu
Cognitive Dysfunction in Parkinson's Disease 10-0771
This research study plans to use simultaneous brain scans and memory tasks to see if stimulating certain areas of the brain improves thinking and memory. This is not a treatment study
Healthy males over 50 with Parkinson's disease on stable doses of medication and have no metal in the body (dental work may be ok).
PI: Kluger, Benzi
  • 303-724-5973
  • isabelle.buard@ucdenver.edu
EFFECTS OF TESTOSTERONE THERAPY IN YOUNG ADOLESCENTS WITH KLINEFELTER SNDROME (47.XXY) 11-0874
This study will study the effects of testosterone therapy on behavior, mood, problem solving, attention span, and motor skills in adolescent males with Klinefelter syndrome in early puberty. During this period in early puberty there is a lot of variability in how and when doctors start testosterone therapy. This study will evaluate if there are benefits to starting testosterone therapy in early puberty.
Participants with Klinefelter syndrome in early puberty (around age 10-15).
PI: Tartaglia, Nicole
  • 720-777-8361
  • susan.howell@childrenscolorado.org
Join a research study that helps you lose weight and become more fit! 13-1551
Seeking volunteers for a research study testing muscle lipid metabolism and diabetes risk before and after a weight loss and exercise training intervention.
Pre-diabetic Age 30-60 BMI over 30 Male or female non-smoking
PI: Bergman, Bryan
  • (303)724-3968
  • diabetesresearch@ucdenver.edu
Managing Celiac Disease May Be More Than a Gluten-free Diet 13-0176
The CeliAction Study is a clinical research study designed to evaluate the safety and effectiveness of an investigational medication for people with celiac disease.
Diagnosed with celiac disease On a gluten-free diet for at least 11 months Have experienced at least one moderate or severe celiac symptom in the past month
PI: Freeman, Stephen
  • 303-724-7875
  • katelyn.cowan@ucdenver.edu
Are you interested in losing weight? 10-0251
Volunteers needed for a research weight loss study to examine the neuronal and behavioral changes that occur with different weight loss interventions (weight loss surgery or diet).
- Are 21-65 years old - Have no metal in your body - Maintained your current weight for the last 6 months - Weigh 350 pounds or less - Have a body mass index of 35 or higher (check it out at http://nhlbisupport.com/bmi/)
PI: Cornier, Marc
  • 303-724-9115
  • Jamie.bechtell@ucdenver.edu
Are you interested in a supervised weight loss intervention? 12-1352
Volunteers needed for a research weight loss study to examine the neuronal and behavioral changes that occur with different weight loss interventions.
- 21-65 years old - Non- smoker - Non- Diabetic - Exercise no more than 1 time a week - Maintained your current weight for the last 6 months - Have a body mass index of 30 -40 (check it out at http://nhlbisupport.com/bmi/
PI: Cornier, Marc
  • 303-724-9024
  • mailto:allison.hild@ucdenver.edu
Are you a Parkinson's patient not requiring symptomatic treatment with drugs? 13-2808
This research study explores the effects of an FDA approved drug on Parkinson's disease.
Recently diagnosed Parkinson's patients who are not taking any drugs for symptomatic relief or are willing to go off drugs for the duration of the study with neurologist approval. We are also looking for healthy control participants.
PI: Freed, Curt
  • 303-724-6015
  • Mary.wang@ucdenver.edu
The Health Influences in Puberty "HIP" study 07-0988
Research study about puberty and risk for type 2 diabetes
Healthy boy between 11 and 13 years of age Healthy girl between 9 and 11 years of age
PI: Kelsey, Megan
  • 720-777-6148
  • allison.hilkin@childrenscolorado.org

​Additional Clinical Trails

 Results From Research : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 18, items 1 to 30 of 511.
Protocol TitlePI NameInstitution Number
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 18, items 1 to 30 of 511.
A Randomized Comparison of NeoCart to Microfracture for the Repair of Articular Cartilage Injuries in the Knee. Sponsor Protocol No. 8-01. WIRB Protocol No.20100579
McCarty, Eric12-0796
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Two Doses of Subcutaneous Pulsatile GnRH Administered via OmniPod Pump for Ovulation Induction in Female Subjects with Primary Amenorrhea with Hypogonadotropic Hypogonadism. Sponsor Protocol No. 000070. WIRB Protocol No. 20140452
Santoro, Nanette13-2352
A Phase 1b, multi-center, two parallel group, open-label, drug-drug interaction study to assess the effect of LDE225 on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumors. Sponsor Protocol No. CLDE225A2112. WIRB Protocol No.20130681
Lewis, Karl13-2556
A Randomized Phase 2 Study of Oral AP26113 in Patients with ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Been Treated with Crizotinib. Sponsor Protocol No. AP26113-13-201. WIRB Protocol No.20131562
Camidge, David13-2648
A MULTI-CENTER,OPEN LABEL, FIRST IN HUMAN, PHASE I DOSE ESCALATION STUDY TO INVESTIGATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO6839921, AN MDM2 ANTAGONIST FOLLOWING INTRAVENOUS ADMINISTRATION IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ACUTE MYELOID LEUKEMIA (AML). Sponsor Protocol No. NP28903. WIRB Protocol No. 20140542
Gore, Lia13-2649
A 12-Week Multicenter, Randomized, Double-Blind,Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate to Severe Plaque Psoriasis with a Long-Term Extension Period. Sponsor Protocol No. I1F-MC-RHBC(b). WIRB Protocol No. 20121432
Armstrong, April13-2723
A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcinerurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation- Advancing renal TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen (TRANSFORM). Sponsor Protocol No. CRAD001A2433. WIRB Protocol No. 20140590
Wiseman, Alexander13-2918
A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy. Sponsor Protocol No. D0816C00002. WIRB Protocol No. 20131789
Davidson, Susan13-2969
BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain. WIRB Protocol No. 20140064
Lewis, Karl13-3079
Evaluation of Acute Rejection Rates in de novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix (belatacept) -based Immunosuppression. Sponsor Protocol No, IM103177. WIRB Protocol No. 20132295
Wiseman, Alexander13-3123
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF 3-MONTH SUBCUTANEOUS REGN1033 TREATMENT IN PATIENTS WITH SARCOPENIA. Sponsor Protocol No. R1033-SRC-1239. WIRB Protocol No.20131518
Schwartz, Robert13-3265
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Solid Tumors, Including Glioma, with an IDH1 Mutation Sponsor Protocol No. AG120-C-002 WIRB Protocol No. 20140544
Gore, Lia14-0012
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation. Sponsor Protocol No. AG120-C-001. WIRB Protocol No. 20140421
Pollyea, Daniel14-0013
A Phase Ib dose escalation/randomized phase II multicenter, open-label study of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma. Sponsor Protocol No. CBYL719X2104. WIRB Protocol No.20140692
Jimeno, Antonio14-0034
A safety study for MSB0010445 in combination with Stereotactic Body Radiation in advanced melanoma subjects following prior treatment with ipilimumab Sponsor Protocol No. EMR 062235-005 WIRB Protocol No. 20140683
Lewis, Karl14-0050
Phase 1 study of ONT-10, a liposomal MUC1 cancer vaccine, in patients with solid tumors. Sponsor Protocol No. ONT-10-001. WIRB Protocol No. 20140202
Borges, Virginia14-0063
Maintenance therapy with ONT-10, a liposomal MUC1 cancer vaccine, in patients who have previously received ONT-10. Sponsor Protocol No. ONT-10-002. WIRB Protocol No. 20140221
Borges, Virginia14-0064
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination with Paclitaxel in Patients with Locally Recurrent or Metastatic Breast Cancer. Sponsor Protocol No. 18R5-002. WIRB Protocol No. 20140743
Diamond, Jennifer14-0065
International, multicenter, open-label, treatment-extension study for subjects who completed a Phase 1 or Phase 2 parental study to continue receiving treatment with SAR245408 or SAR245409 as a monotherapy or as a combination regimen. Sponsor Protocol No. TED12414. WIRB Protocol No. 20120931
Gore, Lia14-0079
A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd- Sulfate) in Combination with Docetaxel, Compared with Placebo in Combination with Docetaxel, in Patients receiving second line treatment for Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB – IV)(SELECT-2) Sponsor Protocol No. D1532C0064 WIRB Protocol No. 20121812
Oton, Ana14-0084
A multicenter, randomized, double-blind, placebo-controlled phase III trial of tecemotide versus placebo in subjects with completed concurrent chemo-radiotherapy for unresectable stage III non-small cell lung cancer (NSCLC). Sponsor Protocol No. EMR-63325-021. WIRB Protocol No. 20140155
Oton, Ana14-0085
A RANDOMIZED, DOUBLE-BLIND TRIAL ASSESSING THE IMPACT OF METHOTREXATE DISCONTINUATION ON THE EFFICACY OF SUBCUTANEOUS TOCILIZUMAB WITH METHOTREXATE THERAPY. Sponsor Protocol No. ML28776. WIRB Protocol No. 20132070
Striebich, Christopher14-0087
Evaluation of Potential Allergenicity of New Soybean Varieties Sponsor Protocol No. Monsanto Soy Allergen WIRB Protocol No.20131161
Fleischer, David14-0097
A single arm, open-label, phase II study to assess the efficacy of the dual VEGFR-FGFR tyrosine kinase inhibitor, lucitanib, given orally as a single agent to patients with FGFR1-driven lung cancer. Sponsor Protocol No. E-3810-II-02. WIRB Protocol No. 20140760
Camidge, David14-0100
A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244, Hyd-Sulfate) in Combination with Dacarbazine Compared with Placebo in Combination with Dacarbazine as First Systemic Therapy in Patients with Metastatic Uveal Melanoma (SUMIT) Sponsor Protocol No. D1344C00001 WIRB Protocol No.20141762
Lewis, Karl14-0108
A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects with Advanced Solid Tumors. Sponsor Protocol No. PT-112-101. WIRB Protocol No. 20140867
Camidge, David14-0151
An Open-Label, Randomized, Phase 3 Trial of Nivolumab versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer Sponsor Protocol No. CA209026 WIRB Protocol No. 20140357
Camidge, David14-0243
A MULTICENTER PHASE 1A/1B ASCENDING DOSE STUDY OF DCC-2701 TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS IN PATIENTS WITH ADVANCED SOLID TUMORS Sponsor Protocol No. DCC-2701-01-001 WIRB Protocol No. 20142004
Leong, Stephen14-0244
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors. Sponsor Protocol No. M14-237. WIRB Protocol No.20140725
Weekes, Colin14-0251
Open-label, single-arm extension study to the double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg FTY720 administered orally once daily versus placebo in patients with primary progressive multiple sclerosis. Sponsor Protocol No. CFTY720D2306E1. WIRB Protocol No. 20140779
Corboy, John14-0289


Contact Us

Building 500 - 13001 E. 17th Place, Campus Box C290, Aurora, CO 80045

Learn more